CURX
Curanex Pharmaceuticals Inc0.4059
-0.0170-4.02%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
11.50MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Debt repaid, shares issued
Curanex Pharmaceuticals issued 28,312 shares of common stock to investor Xiaohong Song on September 25, 2025, fulfilling a $200,000 subscription from November 2024 post-IPO, representing 0.1% of outstanding shares under a Section 4(a)(2) exemption. The company prepaid $408,537.32 to settle two $200,000 promissory notes from CEO's wife Dian Ying Jing, wiping out all outstanding debt and avoiding $26,182.68 in future interest. Debt cleared. This bolsters the balance sheet after the August IPO.
8-K
IPO over-allotment exercised
Curanex Pharmaceuticals announced the full exercise of its underwriters' over-allotment option on September 12, 2025, selling 562,500 additional shares at $4.00 each for $2.25 million in gross proceeds. This boosts the IPO total to $17.25 million before expenses, with 28,312,500 common shares now outstanding. Funds will fuel Phyto-N's advancement through FDA studies and Phase I trials for ulcerative colitis. Yet risks loom in clinical uncertainties.
10-Q
Q2 FY2025 results
Curanex Pharmaceuticals posted a Q2 net loss of $60,346, up 36.6% y/y from $44,200, driven by higher general and administrative expenses of $57,658 versus $44,200 last year, while operating cash burn hit $440,029 for the half-year (derived). No revenue yet, as the biotech focuses on preclinical botanical drug development for inflammatory diseases like ulcerative colitis. Cash dipped to $108,862 by quarter-end, offset by $400,000 in shareholder loans at 4.34% maturing 2027, but the August 27, 2025 IPO delivered $12.9M net proceeds to fuel Phyto-N studies and IND filing. Lease costs added modestly to expenses. Controls faltered. Competition in drug development looms large.
ACXP
Acurx Pharmaceuticals, Inc.
3.59-0.10
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
CPMD
Cannapharmarx Inc.
0.00-0.00
CUBT
CURATIVE BIOTECHNOLOGY INC.
0.01+0.00
IMA
ImageneBio, Inc.
6.25+0.08
NXEN
Nexien BioPharma, Inc.
0.00+0.00
TRML
Tourmaline Bio, Inc.
47.98+47.98
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18
XCUR
Exicure, Inc.
6.06+0.33